Charles Schwab Investment Management Inc. Has $20.96 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Charles Schwab Investment Management Inc. grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,028,462 shares of the company’s stock after acquiring an additional 12,652 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Denali Therapeutics were worth $20,960,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in DNLI. Victory Capital Management Inc. boosted its holdings in Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after purchasing an additional 24,767 shares during the last quarter. FMR LLC boosted its holdings in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. Algert Global LLC boosted its holdings in Denali Therapeutics by 82.4% during the third quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,975 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Denali Therapeutics during the fourth quarter worth about $514,000. Finally, JPMorgan Chase & Co. boosted its holdings in Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after purchasing an additional 14,324 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on DNLI. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective on the stock. Robert W. Baird began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price objective on the stock. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Monday, December 16th. B. Riley reaffirmed a “buy” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Finally, Oppenheimer lowered their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Denali Therapeutics Trading Up 2.1 %

Denali Therapeutics stock opened at $14.82 on Thursday. The firm’s 50 day simple moving average is $19.91 and its 200 day simple moving average is $23.77. The firm has a market capitalization of $2.15 billion, a PE ratio of -5.37 and a beta of 1.46. Denali Therapeutics Inc. has a 1-year low of $14.01 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares of the company’s stock, valued at $2,257,778.16. This represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company’s stock, valued at $536,003.17. The trade was a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 in the last quarter. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.